The effect of food on the bioavailability of oral gemifloxacin in healthy volunteers

International Journal of Antimicrobial Agents

Volumn 16, Issue 1, 2000, Pages 45-50

  Allen, A ^a   Bygate, E ^a   Clark, D ^b   Lewis, A ^a   Pay, V ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

Fluoroquinolone; Food interactions; Gemifloxacin; Pharmacokinetics

Indexed keywords

GEMIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL PHARMACOLOGY; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET RESTRICTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG TOLERABILITY; FEMALE; FOOD DRUG INTERACTION; HUMAN; HUMAN EXPERIMENT; LIPID DIET; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VOLUNTEER;

ADULT; ANTI-INFECTIVE AGENTS; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; DIETARY FATS; FEMALE; FLUOROQUINOLONES; FOOD-DRUG INTERACTIONS; HUMANS; MALE; MIDDLE AGED; NAPHTHYRIDINES;

EID: 0033843538     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(00)00181-3     Document Type: Article

References (19)

1. Oh J.I., Paek K.S., Ahn M.J., et al. In vitro and in vivo evaluations of LB20304, a new fluoronaphthyridone. Antimicrob. Agents Chemother. 40:1996;1564-1568.
2. Cormican M.G., Jones R.N. Antimicrobial activity and spectrum of LB20304, a novel fluoronaphthyridone. Antimicrob. Agents Chemother. 41:1997;204-211.
3. Hohl A.F., Frei R., Pünter V., et al. International multicenter investigation of LB20304, a new fluoronaphthyridone. Clin. Microbiol. Infect. 4:1998;280-284.
4. Hardy D., Amsterdam D., Mandell L., Rotstein C. Comparative in vitro activity of gemifloxacin, moxifloxacin, trovafloxacin, sparfloxacin, grepafloxacin, ofloxacin, ciprofloxacin and other antimicrobial agents against bloodstream isolates of Gram-positive cocci. J. Antimicrob. Chemother. 44:((Suppl A)):1999;146. [Abstract P482].
5. Moore T, Niconovich N, Coleman K. SB-265805 (LB20304a): in vitro antibacterial activity against the common respiratory tract pathogens Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis. Poster F-098 at the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA 1998.
6. Critchley IA, Broskey J, Coleman K. SB-265805 (LB20304a): in-vitro activity, intracellular accumulation and killing of Legionella pneumophila in human macrophages. Poster F-100 at the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA 1998.
7. Felmingham D., Robbins M.J., Dencer C., Salman H., Mathias I., Ridgway G.L. In vitro activity of gemifloxacin against S. pneumoniae, H. influenzae, M. catarrhalis, L. pneumophila and Chlamydia spp. J. Antimicrob. Chemother. 44:((Suppl A)):1999;131. [Abstract P408].
8. Naber K.G., Hollauer K., Kirchbauer D., Witte W. In vitro activity of SB-265805 versus gatifloxacin, moxifloxacin, trovafloxacin, ciprofloxacin and ofloxacin against uropathogens. Clin. Microbiol. Infect. 5:(Suppl 3):1999;144.
9. Allen A., Bygate E., Teillol-Foo M., Oliver S.D., Johnson M.R., Ward C. Pharmacokinetics and tolerability of gemifloxacin after administration of single oral doses to healthy volunteers. J. Antimicrob. Chemother. 44:((Suppl A)):1999;137. [Abstract P440].
10. Allen A., Bygate E., Teillol-Foo M., Oliver S.D., Johnson M.R., Ward C. Multiple-dose pharmacokinetics and tolerability of gemifloxacin following oral doses to healthy volunteers. J. Antimicrob. Chemother. 44:((Suppl A)):1999;133. [Abstract P418].
11. Chiou W.L. Critical evaluation of the potential error in pharmacokinetic studies using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve. J. Pharmacokinet. Biopharm. 6:1978;539-547.
12. Radandt J.M., Marchbanks C.R., Dudley M.N. Interactions of fluoroquinolones with other drugs: mechanisms, variability, clinical significance and management. Clin. Infect. Dis. 14:1992;272-284.
13. Ledergerber B., Bettex J.D., Joos B., Flepp M., Luthy R. Effect of standard breakfast on drug absorption and multiple-dose pharmacokinetics of ciprofloxacin. Antimicrob. Agents Chemother. 27:1985;350-352.
14. Hoffken G., Lode H., Wiley R., Glatzel T.D., Sievers D., Olschewski T. Pharmacokinetics and bioavailability of ciprofloxacin and ofloxacin: effect of food and antacid intake. Rev. Infect. Dis. 10:1988;S138-s139.
15. Teng R., Dogolo L.C., Willavize S.A., Friedman H.L., Vincent F. Oral bioavailability of trovafloxacin with and without food in healthy volunteers. J. Antimicrob. Chemother. 39:1997;87-92.
16. Somogyi A.A., Bochner F., Keal J.A., Rolan P.E., Smith M. Effect of food on enoxacin absorption. Antimicrob. Agents Chemother. 31:1987;638-639.
17. Hooper W.D., Dickinson R.G., Eadie M.J. Effect of food on absorption of lomefloxacin. Antimicrob. Agents Chemother. 34:1990;1797-1799.
18. Dudley M.N., Marchbanks C.R., Flor S.C., Beals B. The effect of food or milk on the absorption kinetics of ofloxacin. Eur. J. Clin. Pharmacol. 41:1991;569-571.
19. Sorgel F., Mahr G., Stephan U., Koch H.U., Weisemann H.G. Effect of normal and fat-rich food on the absorption of pefloxacin in humans. Rev. Infect. Dis. 10:1988;S137-138.